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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Through a genome-wide linkage scan, an Icelandic genetic research
group identified two new genes associated with ischemic stroke: the 5-lipoxygenase activating
protein (ALOX5AP) gene and the phosphodiesterase 4D (PDE4D) gene. Because they regulate
arterial inflammation and are closely related to atherosclerosis and plaque instability, these
two mutated genes have become a research hotspot. The purpose of this study was to inves-
tigate the association between the risk of ischemic stroke and single-nucleotide polymor-
phisms (SNPs) in the ALOX5AP and PDE4D genes in a southeastern Chinese population.
Methods: A total of 459 patients with stroke and 462 control individuals were recruited in the
study. Four ALOX5AP SNPs (SG13S32, SG13S42, SG13S89, and SG13S114), and three PDE4D SNPs
(SNP83, SNP87, and SNP45) were studied. SNP genotypes were determined by polymerase chain
reaction amplification followed by allele-specific primer extension, with detection by matrix-
assisted laser desorption/ionization time-of-flight. Data were coded and entered in SPSS Win-
dows (version 16.0). Odds ratios and 95% confidence intervals were calculated using multivar-
iate logistic regression analysis. Generalized multifactor dimensionality reduction (GMDR)
analysis was applied to detect geneegene interactions.of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Wangsong Road No.
.com (X. Yi).
ight ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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Ischemic stroke risk in Chinese population 423Results: No statistically significant differences were found in the SNP genotype frequencies be-
tween cases and controls for the seven SNPs studied. GMDR analysis revealed no evidence of
interactions between these seven polymorphic sites and an increased stroke risk. In addition,
no association between different stroke types and the control group was detected. Results
showed that only the ALOX5AP gene, and specifically the rs9551963 and rs4769060 genotypes,
exhibited significantly different distributions between the stroke and control groups in female
participants.
Conclusion: No association was found between SNPs of ALOX5AP or PDE4D and the risk of over-
all ischemic stroke in a southeastern Chinese population. Interactions between these two
genes were not risk factors for cerebral infarction. In atherothrombotic and small-artery dis-
ease subtypes, none of the seven SNPs was associated with any stroke risk; however, the
ALOX5AP gene might be related to ischemic stroke incidence in females.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Cerebrovascular disease is a significant cause of death and
disability in the Chinese population, with the incidence of
ischemic stroke accounting for 85e90% of all cerebrovas-
cular diseases.1,2 Ischemic stroke has multiple etiologies
and a varying pathogenesis. Predisposition to ischemic
stroke is influenced by various environmental, lifestyle, and
genetic factors. It is likely the result of the combined effect
of multiple geneegene and geneeenvironment in-
teractions. Stroke prevention requires the determination of
risk factors and interventions.3
Genetic susceptibility to ischemic stroke was first shown
in twin pedigree studies in 1992.4 Jerrard-Dunne et al5
found that a family history of stroke increased the risks of
large-artery atherosclerosis cerebral infarction and small-
artery occlusion cerebral infarction by 2.93 and 3.15
times, respectively, in patients 65 years of age. This
finding suggests a genetic component to stroke risk.
Inflammation also plays a key role in atherosclerosis and
stroke.6 Arterial stenosis and atherosclerotic plaque insta-
bility are two causes of cerebral infarction. Genetic varia-
tions in the components of the inflammatory response have
been implicated as stroke risk factors, particularly when
combined with conventional proinflammatory risk
factors.7,8
ALOX5APencodes5-lipoxygenase-activatingprotein,which
activatesarachidonate5-lypoxygenase, leading to leukotriene
synthesis.9 Leukotrienes are secreted by various inflammatory
cell types that cluster at injured sites in blood vessels and have
been implicated in the progression of atherosclerosis.10 A
linkage study identified variations in ALOX5AP tobeassociated
with susceptibility to myocardial infarction.11 A subsequent
study of an Icelandic population found that a four-SNP
ALOX5AP haplotype (termed HapA) doubled the risk of coro-
nary heart disease and incidence of stroke.12
PDE4D encodes phosphodiesterase 4D, which is a mem-
ber of a large superfamily of cyclic nucleotide phosphodi-
esterases. Phosphodiesterase 4D degrades the second
messengers cyclic adenosine monophosphate and cyclic
guanosine monophosphate, which are the main signal
transduction molecules found in many different cell types,
including inflammatory, vascular endothelial, and smooth
muscle cells.13,14 Gretarsdottir et al15 found that certain
SNP haplotypes of PDE4D were associated with carotid andcardiogenic strokes, but not with other stroke subtypes.
However, thus far, studies relating ALOX5AP and PDE4D
gene polymorphisms with the risk of ischemic stroke in
various populations have yielded widely variable conclu-
sions. Most studies have focused on the ALOX5AP HapA and
HapB haplotypes and stroke risk in general, with little focus
on stroke subtypes or sex comparisons.
Many other genes are being studied for their potential
involvement in stroke risk, including ACE, MTHFR, NOTCH3,
b-Fg, ApoE, and CYP2C9. However, ALOX5AP and PDE4D
seem to be most closely related to atherosclerosis because
they are both involved in the inflammatory process.
The purpose of this study was to evaluate the candidacy
of ALOX5AP and PDE4D as stroke susceptibility genes in a
large population of stroke patients and matched controls
from southeastern China, using single-marker association
tests and a caseecontrol design. Prior results from Chinese
populations have not yielded clear findings.16e18 Moreover,
the gene testing methodology was not uniform, making
comparisons difficult. The key points for these association
studies between the two genes and ischemic stroke depend
on sample size, stroke type, control individuals, and which
SNPs are tested. We aimed to determine the single-
nucleotide polymorphism (SNP) genotypes of ALOX5AP and
PDE4D that are associated with increased risks of athero-
thrombotic (AT) and small-artery disease (SAD) ischemic
strokes in a southeastern Chinese population.Materials and methods
Study populations
This study was approved by the Ethical Committee of the
Third Affiliated Hospital of Wenzhou Medical College (Zhe-
jiang, China). Informed consent was obtained from each
patient prior to study enrollment. The study population
comprised 459 stroke patients and 462 controls who were
consecutively admitted to the Department of Neurology of
the Third Affiliated Hospital of Wenzhou Medical College
between March 2010 and November 2012. All participants
were Chinese Han in origin and were unrelated. Exclusion
criteria included arteritis, infection, tumors, blood dis-
eases, serious cardiopulmonary, liver or kidney diseases,
thyroid diseases, and autoimmune diseases.
Table 1 Amplification and allele-specific extension primers used to genotype ALOX5AP and PDE4D SNPs.
SNP Amplification primers Extension primer
ALOX5AP
SG13S32 (rs9551963) F:50-ACGTTGGATGAGTTCTTGACCTCACCAACC-30
R:50-ACGTTGGATGGGGTTCAAGAGAGAAATTCC-30
ACTGGGGAAGGATCTCATC
SG13S42 (rs4769060) F:50-ACGTTGGATGCGTGGTAATGGGTTTTGAGG-30
R:50-ACGTTGGATGGAAGGGTAGAAGTGTCTCAG-30
TGAACTTATTTCAAACCCAAG
SG13S89 (rs4769874) F:50-ACGTTGGATGTTTCAGGCATGCTCTGCACC-30
R:50-ACGTTGGATGCACCAGGGAGCAAGCATTAG-30
GGATTAGCAATGCATTATCACA
SG13S114 (rs10507391) F:50-ACGTTGGATGTCCAGATGTATGTCCAAGCC-30
R:50-ACGTTGGATGCTCTTAAGGTAGGTCTATGG-30
GCCTCTCTTTGCAATTCTA
PDE4D
SNP83 (rs966221) F:50-ACGTTGGATGGTCCTGCTATTAATAGAAAC-30
R:50-ACGTTGGATGTTGGAAGGATCTGCTGCTGG-30
GCTGCTGGATAAACCAC
SNP45 (rs12188950) F:50-ACGTTGGATGGTATTGCTGCCATCATTTTAC-30
R:50-ACGTTGGATGAATAAATGCTTTGGGGACAG-30
AGCAGATAGGGCACA
SNP87 (rs2910829) F:50-ACGTTGGATGCTCTAACCAAGTGCTTGCTG-30
R:50-ACGTTGGATGTGAGGAAGAATAATGGATGC-30
ACATTCATAACATCTACACAA
ALOX5AP Z 5-lipoxygenase activating protein; PDE4D Z phosphodiesterase 4D; SNP Z single-nucleotide polymorphism.
424 M. Shao et al.Cerebral infarction for all patients was confirmed by
computed tomography andmagnetic resonance imaging, and
was classified according to a modified version of the Trial of
Org 10172 in Acute Stroke Treatment (TOAST) classifica-
tion.19 Two subtypes of cerebral infarction (i.e., ATand SAD)
were included. Patientswith cardiogenic cerebral embolism,
cerebral infarction of unclear etiology, or a previous history
of stroke were excluded. Of the 459 patients diagnosed with
cerebral infarction, 276 were male and 183 female, with an
average age of 68.56  10.97 years.
The controls had no family history of stroke and were
unrelated to the stroke patients. A total of 462 healthy
volunteers were ascertained, including 276 males and 186
females with an average age of 63.82  9.22 years. Vascular
risk factors collected from each individual included age,
sex, hypertension, diabetes mellitus (DM), cigarette smok-
ing, alcohol intake, total plasma cholesterol, low-density
lipoprotein cholesterol (LDL-C), triglycerides, and blood
platelets levels. Hypertension was defined as a mean of
three independent measures of blood pressure of 140/
90 mmHg or the use of antihypertensive drugs. DM was
diagnosed by a fasting glucose level of >7.8 mmol/L or that
of >11.1 mmol/L 2 hours after an oral glucose challenge.
Cigarette smoking was defined as having smoked at least
one cigarette a day for more than 1 year. Alcohol con-
sumption was defined as drinking alcohol at least 12 times
in the past year.20 Cerebral infarction was ruled out in the
control population based on the history, physical exami-
nation, and laboratory results described above.Marker selection and genotyping
For ALOX5AP, four SNPs were studied: rs9551963A/C,
rs4769060A/G, rs4769874A/G, and rs10507391A/T. For
PDE4D, three SNPswere studied: rs966221C/T, rs12188950C/
T, and rs2910829C/T (http://www.ncbi.nlm.nih.gov/snp/).
Previous studies demonstrated significant associations be-
tween these SNPs and stroke, and that mutations in thesegenes may increase the incidence of ischemic stroke.18,21,22
Additional rationale for studying these SNPs was based on
each SNP’s minor allele frequency (MAF). The MAF for
ALOX5AP SG13S89 (rs4769874) is 0.051, the lowest for all
SNPs in the study (http://www.ncbi.nlm.nih.gov/snp/).
Genomic DNA was extracted from peripheral blood using
a modified phenol/chloroform method23 and purified using
the UNIQ-10 kit (Sangon Biotech Co., Ltd, Shanghai, China).
Amplification of the target sequences was performed in a
multiplex reaction containing 5 ng of DNA, 0.95 mL of water,
0.625 mL of polymerase chain reaction (PCR) buffer con-
taining 15 mM MgCl2, 1 mL of 2.5 mM deoxy-ribonucleoside
triphosphate (dNTP), 0.325 mL of 25 mM MgCl2, 1 mL of PCR
primers (Table 1), and 0.5 U HotStar Taq (Qiagen Co., Ltd,
Shanghai, China). The reaction was incubated at 94C for 15
minutes, followed by 45 cycles at 94C for 20 seconds, at
56C for 30 seconds, and at 72C for 1 minute, and a final
incubation at 72C for 3 minutes. After PCR amplification,
remaining dNTPs were dephosphorylated by adding 1.53 mL
of water, 0.17 mL of SAP buffer, and 0.3 units of shrimp
alkaline phosphatase (Sequenom Inc., San Diego, CA, USA).
After incubation at 37C for 40 minutes, the enzyme was
deactivated by incubating at 85C for 5 minutes.
Each SNP gene possessed a specific genotype, with two
amplification primers and one extension primer (Table 1).
The extension primers were then added to the reaction in a
buffer containing 0.755 mL of water, 0.2 mL of 10 iPLEX
buffer, 0.2 mL of termination mix, 0.041 mL of iPLEX enzyme
(Sequenom Inc.), and 0.804 mL of 10 mM extension primer.
The single-base extension reaction consisted of an initial
denaturation at 94C for 30 seconds, and then at 94C for 5
seconds, followed by five cycles at 52C for 5 seconds and
at 80C for 5 seconds (a total of 40 cycles), and a final
extension at 72C for 3 minutes.
The reaction mix was desalted by adding 6 mg of a cation
exchange resin (Sequenom Inc.), mixed, and resuspended
in 25 mL of water. At the completion of the primer extension
reaction, the completed reactions were spotted onto a 384-
well spectroCHIP (Sequenom Inc.) using a MassARRAY
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matrix-assisted laser desorption ionization time-of-flight
mass spectrometer. Genotype calling was performed in real
time using the MassARRAY RT software version 3.0.0.4 and
analyzed using the MassARRAY Typer software version 3.4
(Sequenom Inc.).24
Statistical analysis
Allele and genotype frequencies were calculated for each
locus. The HardyeWeinberg equilibrium was tested with
Chi-square tests. Continuous variables were expressed as
the mean  standard deviation (SD) and compared by an
unpaired Student t test, unless otherwise indicated. Cate-
gorical variables were assessed by the Chi-square test or
Fisher’s exact test. Biological and clinical variables were
compared between the case and control groups by the
Student t test and Chi-square test for continuous and cat-
egorical variables, respectively.
Clinical characteristics and genotype distribution in both
groups were analyzed by a univariate analysis. Multivariate
logistic regression analyses were performed with adjust-
ment for certain risk factors, including sex, hypertension,
DM, smoking, drinking, and LDL-C, to assess the indepen-
dent contribution of genotypes and haplotypes to stroke.
The odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated from the b coefficients and standard er-
rors. All statistical tests were performed with the SPSS
version 16.0 software package (SPSS Inc., Chicago, IL, USA).
A two-tailed p value of <0.05 was considered statistically
significant. GMDR analysis was applied to detect geneegene
interactions.
Results
Clinical characteristics of the participants
Demographic information and clinical characteristics of all
study participants are presented in Table 2. A differenceTable 2 Clinical characteristics of the participants.
Characteristic Cases
(n Z 459)
Controls
(n Z 462)
p
Age (y) 68.56  10.97 63.82  9.22 <0.001
Male sex 60.13 59.74 0.904
Hypertension 77.56 24.19 <0.001
Diabetes mellitus 31.81 18.61 <0.001
Cigarette
smoking
44.88 42.86 0.536
Alcohol intake 47.28 46.75 0.874
TC (mmol/L) 4.73  1.31 4.86  1.40 0.140
LDL-C (mmol/L) 2.91  1.12 3.03  1.11 0.090
TG (mmol/L) 1.79  1.02 1.79  0.97 0.993
PLT (109/L) 191.78  62.04 196.91  45.68 0.183
Data are presented as % or mean  SD.
LDL-C Z low-density lipoprotein cholesterol; PLT Z blood
platelet; SD Z standard deviation; TC Z total plasma choles-
terol; TG Z triglycerides.was observed in the distribution of age (p < 0.001) between
cases and controls, but not in that of sex (p Z 0.904). As
expected, stroke patients had a higher prevalence of risk
factors for vascular diseases, including increased age, his-
tory of hypertension, and DM (p < 0.001). Notably, differ-
ences in the presence of conventional risk factors,
including smoking and alcohol intake, total plasma choles-
terol, LDL-C, triglycerides, and blood platelets, were not
statistically different between cases and controls
(p > 0.05).
Associations between ALOX5AP and PDE4D SNP
genotypes and risk of overall stroke
Genotyping results for the ALOX5AP and PDE4D SNPs for all
study participants are shown in Table 3. Genotype distri-
butions in the control population were consistent with the
HardyeWeinberg equilibrium. Multivariable logistic regres-
sion analysis revealed that the genotype frequencies be-
tween cases and controls were not significantly different
for any of the SNPs tested.
GMDR analysis
We used GMDR to determine any geneegene interactions
that might increase stroke risk. With covariable adjust-
ments for age, hypertension, and DM, we did not find evi-
dence of any ALOX5APePDE4D interaction that might
increase stroke risk in this southeastern Chinese population
(Table 4).
Stroke types and sex dependence in ethnic Chinese
populations
This study recruited only patients attributed to AT and SAD
subtypes based on the TOAST classification. In total, 276 AT
and 183 SAD subtypes were identified. Following stratifi-
cation by stroke type, we found that neither AT nor SAD
groups exhibited a different distribution of the seven SNPs
compared to the control group (Table 5).
The ALOX5AP gene, and specifically the rs9551963 and
rs4769060 genotypes, exhibited significantly different dis-
tributions between the stroke and control groups in female
patients following sex stratification (Table 6; p < 0.05). The
Rs9551963 C allele showed a significant relationship with
female stroke (p Z 0.000); however, no significant rela-
tionship was detected in the rs4769060 A allele (pZ 0.721).
Based on the significant differences in genotypic distribu-
tions between groups, an association with cerebral infarc-
tion in the female group was indicated.
Discussion
Stroke is a complex clinical syndrome with various genetic
and clinical risk factors including, but not limited to, age,
hypertension, DM, and hyperlipidemia. Several recent
studies have shown that genetic factors play an important
role in stroke. ALOX5AP, a gene involved in the leuko-
triene synthesis pathway, and PDE4D, involved in signal
transduction by degrading cyclic adenosine
Table 3 ALOX5AP and PDE4D SNP genotype frequencies in ischemic stroke and control groups.a
Gene SNP Genotype No. of cases (%) No. of controls (%) p OR (95% CI)
ALOX5AP SG13S32 (rs9551963) AC 230 (0.50) 214 (0.46)
CC 69 (0.15) 80 (0.17)
AA 160 (0.35) 168 (0.36) 0.455 d
A alleles 550 (0.60) 550 (0.60) 0.955 1.005 (0.834e1.212)
SG13S89 (rs4769874) AG 22 (0.048) 16 (0.035)
GG 437 (0.952) 446 (0.965) 0.244 1.470 (0.766e2.821)
A alleles 22 (0.024) 16 (0.017) 0.322 1.387 (0.724e2.659)
SG13S42 (rs4769060) AA 172 (0.37) 197 (0.43)
AG 225 (0.49) 209 (0.45)
GG 62 (0.14) 56 (0.12) 0.275 d
A alleles 569 (0.62) 603 (0.65) 0.112 0.857 (0.709e1.037)
SG13S114 (rs10507391) AA 84 (0.18) 69 (0.15)
TT 146 (0.32) 151 (0.33)
AT 229 (0.50) 242 (0.52) 0.386 d
A alleles 397 (0.43) 380 (0.41) 0.399 1.047 (0.900e1.303)
PDE4D SNP83 (rs966221) CC 16 (0.03) 29 (0.06)
TT 304 (0.66) 300 (0.65)
CT 139 (0.30) 133 (0.29) 0.142 d
C alleles 171 (0.19) 191 (0.21) 0.250 0.874 (0.694e1.100)
SNP45 (rs12188950) CC 459 (1.00) 460 (1.00)
CT 0 (0.00) 2 (0.00) 0.499 1.004 (0.998e1.010)
C alleles 918 (1.00) 922 (1.00) 0.500 1.002 (0.999e1.005)
SNP87 (rs2910829) CC 308 (0.67) 314 (0.68)
TT 12 (0.03) 10 (0.02)
CT 139 (0.30) 138 (0.30) 0.890 d
C alleles 755 (0.82) 766 (0.83) 0.564 0.931 (0.731e1.186)
ALOX5AP Z 5-lipoxygenase activating protein; CI Z confidence interval; OR Z odds ratio; PDE4D Z phosphodiesterase 4D;
SNP Z single-nucleotide polymorphism.
a Statistical analysis was performed by Chi-square test between controls and patients with ischemic stroke.
426 M. Shao et al.monophosphate and cyclic guanosine monophosphate,
were identified through linkage analysis to confer risk of
stroke in an Icelandic population.12,15 In this study, we
attempted to determine whether certain SNPs within
these two genes, ALOX5AP and PDE4D, were associated
with an increased risk of overall stroke in a southeast
Chinese population. The SNPs chosen for this study have
appeared in several non-European studies of stroke risk
and all have an MAF of over 5%. We also thought that there
might be some measurable geneegene interactionTable 4 Generalized multifactor dimensionality reduction analy
PDE4D SNP genotypes and risk of ischemic stroke.
Best model Training balanced
accuracy
Testing
accura
1 0.5325 0.4887
2, 3 0.5678 0.5216
2, 3, 4 0.5907 0.5002
1, 2, 3, 5 0.6368 0.5693
1, 2, 3, 4, 5 0.6610 0.5565
1, 2, 3, 4, 5, 6 0.6666 0.5585
1, 2, 3, 4, 5, 6, 7 0.6666 0.5585
Model components: 1, ALOX5AP SG13S42; 2, ALOX5AP SG13S114; 3, P
SG13S89; and 7, PDE4D SNP45.
ALOX5AP Z 5-lipoxygenase activating protein; PDE4D Z phosphodiesbetween ALOX5AP and PDE4D and risk of stroke, because
both genes are involved in inflammation. However, in
contrast to the European studies, we found neither any
association between overall stroke susceptibility and the
seven SNPs studied, nor any evidence of interactions be-
tween the two genes influencing stroke risk.
In addition to the SNPs comprising the HapA and HapB risk
haplotypes identified in the European studies, other
ALOX5AP SNPs have been associated with ischemic stroke in
various populations.25e27 Contrasting results reporting nosis showing no evidence of interactions between ALOX5AP and
balanced
cy
Sign test (p) Cross-validation
consistency
4 (0.8281) 6/10
7 (0.1719) 7/10
5 (0.6230) 5/10
8 (0.0547) 10/10
8 (0.0547) 10/10
8 (0.0547) 10/10
8 (0.0547) 10/10
DE4D SNP83; 4, ALOX5AP SG13S32; 5, PDE4D SNP87; 6, ALOX5AP
terase 4D; SNP Z single-nucleotide polymorphism.
Table 5 Subtype-dependent ALOX5AP and PDE4D SNP genotypic frequencies in ischemic stroke.
Gene SNP Genotype AT (%) SAD (%) p OR (95% CI)
ALOX5AP SG13S32 (rs9551963) AC 133 (0.482) 103 (0.563)
CC 35 (0.127) 24 (0.131)
AA 108 (0.391) 56 (0.306) 0.160
C alleles 203 (0.368) 151 (0.413) 0.172 0.828 (0.632e1.086)
SG13S89 (rs4769874) AG 9 (0.033) 11 (0.060)
GG 267 (0.967) 172 (0.940) 0.158 0.527 (0.214e1.298)
A alleles 9 (0.016) 11 (0.030) 0.162 0.535 (0.219e1.304)
SG13S42 (rs4769060) AA 113 (0.450) 60 (0.328)
AG 129 (0.467) 95 (0.519)
GG 34 (0.123) 28 (0.153) 0.195
A alleles 355 (0.643) 215 (0.587) 0.089 1.266 (0.965e1.660)
SG13S114 (rs10507391) AA 55 (0.199) 26 (0.142)
TT 92 (0.333) 53 (0.290)
AT 129 (0.468) 104 (0.568) 0.086
A alleles 239 (0.433) 156 (0.426) 0.858 1.025 (0.785e1.338)
PDE4D SNP83 (rs966221) CC 10 (0.036) 7 (0.038)
TT 190 (0.689) 108 (0.590)
CT 76 (0.275) 68 (0.372) 0.086
C alleles 96 (0.174) 82 (0.224) 0.060 0.729 (0.524e1.014)
SNP45 (rs12188950) CC 276 (1.000) 183 (1.000)
CT 0 (0.000) 0 (0.000) d d
C alleles 552 (1.000) 366 (0.100) d d
SNP87 (rs2910829) CC 195 (0.707) 114 (0.623)
TT 9 (0.032) 8 (0.044)
CT 72 (0.261) 61 (0.333) 0.174
C alleles 462 (0.837) 289 (0.790) 0.069 1.368 (0.976e1.918)
ALOX5AP Z 5-lipoxygenase activating protein; AT Z atherothrombotic; CI Z confidence interval; OR Z odds ratio;
PDE4D Z phosphodiesterase 4D; SAD Z small-artery disease; SNP Z single-nucleotide polymorphism.
Table 6 Sex-dependent ALOX5AP and PDE4D SNP genotypic frequencies in ischemic stroke and control groups.
Gene SNP Genotype CasesdF (%) ControlsdF (%) p OR (95% CI)
ALOX5AP SG13S32 (rs9551963) AC 106 (0.579) 76 (0.409)
CC 59 (0.323) 46 (0.247)
AA 18 (0.098) 64 (0.344) 0.000
C alleles 224 (0.612) 168 (0.452) 0.000 1.915 (1.429e2.568)
SG13S89 (rs4769874) AG 14 (0.076) 11 (0.059)
GG 169 (0.924) 175 (0.941) 0.440
A alleles 14 (0.038) 11 (0.030) 0.437 0.859 (0.586e1.260)
SG13S42 (rs4769060) AA 59 (0.323) 68 (0.366)
AG 111 (0.606) 92 (0.494)
GG 13 (0.071) 26 (0.140) 0.035
A alleles 229 (0.626) 228 (0.613) 0.721 1.056 (0.784e1.421)
SG13S114 (rs10507391) AA 36 (0.197) 35 (0.188)
TT 62 (0.339) 57 (0.307)
AT 85 (0.464) 94 (0.505) 0.722
A alleles 157 (0.429) 164 (0.441) 0.744 0.953 (0.712e1.275)
PDE4D SNP83 (rs966221) CC 8 (0.044) 18 (0.097)
TT 141 (0.770) 134 (0.720)
CT 34 (0.186) 34 (0.183) 0.135
C alleles 50 (0.137) 70 (0.188) 0.058 0.683 (0.460e1.014)
SNP45 (rs12188950) CC 183 (1.000) 184 (0.995)
CT 0 (0.00) 2 (0.005) 0.485
C alleles 366 (1.000) 370 (0.995) 0.486 0.503 (0.468e0.540)
SNP87 (rs2910829) CC 122 (0.667) 115 (0.618)
TT 3 (0.016) 5 (0.027)
CT 58 (0.317) 66 (0.355) 0.549
C alleles 302 (0.825) 296 (0.796) 0.308 1.212 (0.838e1.753)
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results, likemany others, showno evidence of a link between
ALOX5AP SNP genotypes and risk of stroke in a southeastern
Chinese population. The association between PDE4D SNPs
and stroke is similarly debated in the literature.15,27,31e35
Our analysis of three PDE4D SNPs also did not yield any evi-
dence of an association with stroke risk.
Although the link between ALOX5AP gene mutations and
stroke risk is still debated, the mechanism by which it may
affect cerebral infarction is through its role in leukotriene
formation. Inflammation may alter the vascular perme-
ability, promoting cerebral atherosclerosis. PDE4D also me-
diates inflammation by promoting the proliferation of
smooth muscle cells and the inflammatory response through
regulation of intracellular second messenger activity.
Because both these two genes are involved in inflammation,
an interaction between ALOX5AP and PDE4D may increase
stroke susceptibility by promoting atherosclerosis and/or
regulating plaque stability. Although this hypothesis is
attractive, our GMDR analysis did not provide any evidence
supporting this relationship. This is a novel finding; we found
no other reports in the literature studying the interactions
between these two genes and influence of stroke risk.
A study conducted in an East Indian population found
that SNP 83 was significantly associated with these stroke
subtypes, but the association with other subtypes was
determined to be insignificant.36 The Taiwan population
provides preliminary evidence suggesting that the ALOX5AP
gene polymorphisms were associated with AT stroke.37
However, a Swedish study indicated that SNP45 had no ef-
fect on ischemic stroke, results being derived from either
pooled multicenter data or a meta-analysis. In addition,
significant associations were not found when evaluating
patients from the three different TOAST subgroups sepa-
rately.38 A study in Han Chinese of eastern China showed a
negative association between the ALOX5AP variants and
ischemic stroke risk. In addition, no relationship between
different TOAST subtypes was detected, and a sex stratifi-
cation analysis showed an absence of increased sex
incidence.18 Given these differences, additional studies
attempted to determine whether the seven SNPs exhibited
a relationship with alternative TOAST classifications.
Meanwhile, our study concluded that the risks associated
with the ALOX5AP gene were sex dependent in ethnic
Chinese populations. The ALOX5AP gene, which included
rs9551963 and rs4769060 genotypes, might add to ischemic
stroke incidence in females.
Published accounts of associations between stroke risk and
ALOX5AP or PDE4D gene polymorphisms offer widely variable
conclusions. However, it is difficult to compare these studies
directly, due to differences in population, race, and gene
target(s). In this study, we attempted to minimize bias due to
population structure by recruiting controls and patients from
the same geographical region of China. Our results should be
validated in a larger, multicenter study.Acknowledgments
This work was supported by Zhejiang Province Natural Sci-
ence Foundation (No. Y2110379). The authors offer sincere
thanks to all their colleagues in the Department ofNeurology of the Third Affiliated Hospital of Wenzhou
Medical College and to Sangon Biotech Co., Ltd. (Shanghai,
China). They thank Medjaden Bioscience Limited for
assisting in the preparation of this manuscript.References
1. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM,
et al. Change in stroke incidence, mortality, case-fatality,
severity, and risk factors in Oxfordshire, UK from 1981 to
2004 (Oxford Vascular Study). Lancet 2004;363:1925e33.
2. Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO.
Stroke incidence, prevalence, and survival: secular trends in
Rochester, Minnesota, through 1989. Stroke 1996;27:373e80.
3. Ross OA, Worrall BB, Meschia JF. Advancing stroke therapeutics
through genetic understanding. Curr Drug Targets 2007;8:
850e9.
4. Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study
of twins and stroke. Stroke 1992;23:221e3.
5. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the
genetic component of ischemic stroke subtypes: a family his-
tory study. Stroke 2003;34:1364e9.
6. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb
Vasc Biol 2012;32:2045e51.
7. Jerrard-Dunne P, Sitzer M, Risley P, Buehler A, von Kegler S,
Markus HS. Inflammatory gene load is associated with
enhanced inflammation and early carotid atherosclerosis in
smokers. Stroke 2004;35:2438e43.
8. Jerrard-Dunne P, Sitzer M, Risley P, Steckel DA, Buehler A,
von Kegler S, et al. Interleukin-6 promoter polymorphism
modulates the effects of heavy alcohol consumption on early
carotid artery atherosclerosis: the Carotid Atherosclerosis
Progression Study (CAPS). Stroke 2003;34:402e7.
9. Dixon WT, Demetrick DJ, Ohyama K, Sikora LK, Jerry LM.
Biosynthesis, glycosylation and intracellular processing of the
neuroglandular antigen, a human melanoma-associated anti-
gen. Cancer Res 1990;50:4557e65.
10. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A,
Ruhling K, et al. Expanding expression of the 5-lipoxygenase
pathway within the arterial wall during human atherogenesis.
Proc Natl Acad Sci USA 2003;100:1238e43.
11. Topol EJ, Smith J, Plown EF, Wang QK. Genetic susceptibility to
myocardial infarction and coronary artery disease. Hum Mol
Genet 2006;15:117e23.
12. Helgadottir A, Manolescu A, Thorleifaeon G, Gretarsdottir S,
Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-
lipoxygenaee activating protein confers risk of myocardial
infarction and stroke. Nat Genet 2004;36:233e9.
13. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC,
et al. Expression of phosphodiesterase 4d (PDE4D) is regulated
by both the cyclic AMP-dependent protein kinase and mitogen-
activated protein kinase signaling pathways. A potential mech-
anism allowing for the coordinated regulation of pde4d activity
and expression in cells. J Biol Chem 2000;275:26615e24.
14. Landells LJ, Szilagy CM, Jones NA, Banner KH, Allen JM,
Doherty A, et al. Identification and quantification of phos-
phodiesterase 4 subtypes in CD4 and CD8 lymphocytes from
healthy and asthmatic subjects. Br J Pharmacol 2001;133:
722e9.
15. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A,
Jonsdottir S, Jonsdottir T, et al. The gene encoding phospho-
diesterase 4D confers risk of ischemic stroke. Nat Genet 2003;
35:131e8.
16. Sun Y, Huang Y, Chen X, Liu Y, Lu X, Shi Y, et al. Association
between the PDE4D gene and ischemic stroke in the Chinese
Han population. Clin Sci 2009;117:265e72.
Ischemic stroke risk in Chinese population 42917. Sun H, Wu H, Zhang J, Wang J, Lu Y, Ding H, et al. A tagging SNP
in ALOX5AP and risk of stroke; a haplotype-based analysis
among eastern Chinese Han population. Mol Biol Rep 2011;38:
4731e8.
18. Wang G, Wang Y, Sun H, Cao W, Zhang J, Xiao H, et al. Variants
of the arachidonate 5-lipoxygenase-activating protein
(ALOX5AP) gene and risk of ischemic stroke in Han Chinese of
eastern China. J Biomed Res 2011;25:319e27.
19. Han SW, Kim SH, Lee JY, Chu CK, Yang JH, Shin HY, et al. A new
subtype classification of ischemic stroke based on treatment
and etiologic mechanism. Eur Neurol 2007;57:96e102.
20. Kelly TN, Gu D, Chen J, Huang JF, Chen JC, Duan X, et al.
Cigarette smoking and risk of stroke in the Chinese adult
population. Stroke 2008;39:1688e93.
21. Kostulas K, Gretarsdottir S, Kostulas V, Manolescu A,
Helgadottir A, Thorleifsson G, et al. PDE4D and ALOX5AP ge-
netic variants and risk for ischemic cerebrovascular disease in
Sweden. J Neurol Sci 2007;263:113e7.
22. Lo¨kvist H, Smith JG, Luthman H, Ho¨glund P, Norrving B,
Kristoffersson U, et al. Ischaemic stroke in hypertensive pa-
tients is associated with variations in the PDE4D genome re-
gion. Eur J Hum Genet 2008;16:1117e25.
23. Di Pietro F, Ortenzi F, Tilio M, Concetti F, Napolioni V. Genomic
DNA extraction from whole blood stored from 15- to 30-years
at e20C by rapid phenol-chloroform protocol: a useful tool for
genetic epidemiology studies. Mol Cell Probes 2011;25:44e8.
24. Aggarwal S, Ali S, Chopra R, Srivastava A, Kalaiarasan P,
Malhotra D, et al. Genetic variations and interactions in anti-
inflammatory cytokine pathway genes in the outcome of
leprosy: a study conducted on a MassARRAY platform. J Infect
Dis 2011;204:1264e73.
25. Kaushal R, Pal P, Alwell K, Haverbusch M, Flaherty M, MoomawC,
et al. Association of ALOX5APwith ischemic stroke: a population-
based case-control study. Hum Genet 2007;121:601e7.
26. Domingues-Montanari S, Fernandez-Cadenas I, del Rio-
Espinola A, Corbeto N, Krug T, Manso H, et al. Association of a
genetic variant in the ALOX5AP with higher risk of ischemic
stroke: a caseecontrol, meta-analysis and functional study.
Cerebrovasc Dis 2010;29:528e37.
27. Meschia JF, Brott TG,BrownJrRD,CrookR,Worrall BB, Kissela B,
et al. Phosphodiesterase 4D and 5-lipoxygenase activating pro-
tein in ischemic stroke. Ann Neurol 2005;58:351e61.28. He YL, Zhu M, Jin XP, Zhou YL. Relationship of polymorphism of
SG13S114A/T in ALOX5AP gene with atherosclerotic cerebral
infarction. Zhejiang Da Xue Xue Bao Yi Xue Ban 2009;38:
630e3.
29. Barral S, Ferna´dez-Cadenas I, Bis JC, Montaner J, Ikram AM,
Launer LJ, et al. No association of ALOX5AP polymorphisms
with risk of MRI-defined brain infarcts. Neurobiol Aging 2012;
33:629. e1e3.
30. Bisoendial RJ, Tanck MW, Golledge J, Broekhuizen LN,
Legemate DA, Stroes ES, et al. The association between the
gene encoding 5-lipoxygenase activating protein and abdom-
inal aortic aneurysms. Atherosclerosis 2012;220:425e8.
31. Quarta G, Stanzione R, Evangelista A, Zanda B, Di
Angelantonio E, Marchitti S, et al. Phosphodiesterase 4D and 5-
lipoxygenase activating protein genes and risk of ischemic
stroke in Sardinians. Eur J Hum Genet 2009;17:1448e53.
32. Saleheen D, Bukhari S, Haider SR, Nazir A, Khanum S,
Shafqat S, et al. Association of phosphodiesterase 4D gene with
ischemic stroke in a Pakistani population. Stroke 2005;36:
2275e7.
33. Xu X, Li X, Li J, Ou R, Sheng W. Meta-analysis of association
between variation in the PDE4D gene and ischemic cerebral
infarction risk in Asian populations. Neurogenetics 2010;11:
327e33.
34. Staton JM, Sayer MS, Hankey GJ, Attia J, Thakkinstian A, Yi Q,
et al. Association between phosphodiesterase 4D gene and
ischemic stroke. J Neurol Neurosurg Psychiatry 2006;77:1067e9.
35. Kalita J, Somarajan BI, Kumar B, Kumar S, Mittal B, Misra UK.
Phosphodiesterase 4D gene polymorphism in relation to intra-
cranial and extracranial atherosclerosis in ischemic stroke. Dis
Markers 2011;31:191e7.
36. Munshi A, Babu MS, Kaul S, Shafi G, Anila AN, Alladi S, et al.
Phosphodiesterase 4D (PDE4D) gene variants and the risk of
ischemic stroke in a South Indian population. J Neurol Sci 2009;
285:142e5.
37. Lo¨kvist H, Olsson S, Ho¨lund P, Melander O, Jern C, Sjo¨gren M,
et al. A large-sample assessment of possible association be-
tween ischaemic stroke and rs12188950 in the PDE4D gene. Eur
J Hum Genet 2012;20:783e9.
38. Lee JD, Lee TH, Huang YC, Chang YJ, Chang CH, Hsu HL, et al.
ALOX5AP genetic variants and risk of atherothrombotic stroke
in the Taiwanese population. J Clin Neurosci 2011;18:1634e8.
